Surface Oncology to Present at the Cowen IO Next Summit
Surface Oncology (Nasdaq: SURF) will participate in the Cowen 4th Annual IO Next Summit on November 13, 2020, at 10:45 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF) will participate in the Cowen 4th Annual IO Next Summit on November 13, 2020, at 10:45 a.m. ET. CEO Jeff Goater and CMO Robert Ross, M.D., will discuss the company's lead immunotherapy programs, SRF617 (CD39) and SRF388 (IL-27). The event will be accessible via live audio and archived webcasts on the company's investor relations website.
Surface Oncology focuses on developing innovative immunotherapies targeting the tumor microenvironment, with additional collaborations and preclinical programs aiming for significant anti-tumor responses.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was +4.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in a fireside chat at the upcoming Cowen 4th Annual IO Next Summit on Friday, November 13, 2020 at 10:45 a.m. ET. The discussion will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27).
The live audio and subsequent archived webcasts of the fireside chat will be accessible from the events page of the Company’s investor relations website, investors.surfaceoncology.com/news-events/events.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting PVRIG, also known as CD112R (SRF813)), or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698
Media
Matthew Corcoran
mcorcoran@tenbridgecommunications.com
617-866-7350
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.